SOUTH SAN FRANCISCO, Calif., Aug. 28, 2019 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced that Gerald McMahon, Ph.D., President and Chief Executive Officer, will participate in two upcoming investor conferences:
- Institutional investor meetings at Citi’s 14th Annual Biotech Conference in Boston on September 4, 2019; and
- A fireside chat at the Baird 2019 Global Healthcare Conference in New York on September 5, 2019 at 1:25 p.m. ET / 10:25 a.m. PT.
A live audio webcast and replay of the fireside chat will be available in the Investors section of Harpoon Therapeutics’ website at www.harpoontx.com.
About Harpoon Therapeutics
Harpoon Therapeutics is a clinical-stage immunotherapy company developing a novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. T cell engagers are engineered proteins that direct a patient’s own T cells to kill target cells that express specific proteins, or antigens, carried by the target cells. Using its proprietary Tri-specific T cell Activating Construct (TriTAC™) platform, Harpoon is developing a pipeline of novel T cell engagers, or TriTACs, initially focused on the treatment of solid tumors and hematologic malignancies. For additional information about Harpoon Therapeutics, please visit www.harpoontx.com.
Harpoon Therapeutics, Inc.
Chief Financial Officer
Robert H. Uhl
Source: Harpoon Therapeutics